Ceftazidime for Injection USP and Dextrose for Injection USP — Class I drug recall D-1257-2020
Terminated recall by B. Braun Medical Inc, reported 2020-05-06, distributed nationwide. Failed Stability Specifications: Out-of-Specification (OOS) results for High Molecular Weight Polymers.
| Recall number | D-1257-2020 |
|---|---|
| Product type | Drug |
| Classification | Class I |
| Status | Terminated |
| Voluntary or mandated | Voluntary |
| Recalling firm | B. Braun Medical Inc, Irvine, CA, United States |
| Recall initiated | 2020-04-18 |
| Classified | 2020-04-28 |
| Reported by FDA | 2020-05-06 |
| Terminated | 2021-10-21 |
| Distributed | Nationwide (US) |
| Quantity | 22,488 duplex |
| Reason classes | specification failure |
| NDC | 00264-3145-11 |
| Lot numbers | H8J812 |
| Expiration dates | 2020-07-31 |
Product
Ceftazidime for Injection USP and Dextrose for Injection USP, 2 g, 50 mL Duplex Container, RX only, B Braun Medical Inc., Bethlehem, PA 18018-3524, NDC 0264-3145-11
Reason for recall
Failed Stability Specifications: Out-of-Specification (OOS) results for High Molecular Weight Polymers.
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-1257-2020. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.